Video

Dr. Schaider Discusses Drug Resistance for Melanoma

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

According to Schaider, adaptive drug resistance occurs at the beginning of treatment. Drug resistance generally occurs in the first 3 to 6 weeks.

More studies need to be conducted to determine why the cells become resistant to certain treatments, states Schaider.

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS